Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Pemetrexed Action Pathway
Homo sapiens
Drug Action Pathway
Pemetrexed is an antifolate, it contains a pyrrolopyrimidine base within its structure that inhibits DNA synthesis and de novo biosynthesis of nucleotides. Once inside the cell via a folate transporter, it is converted to by folylpolyglutamate synthétase into its polyglutamate form. This new form is better retained in the cells and goes on to inhibit enzymes such as dihydrofolate reductase, thymidylate synthase and bifunctional purine biosynthesis protein (PURH). This drug is used to treat cancer specifically that of lung cancer or mesothelioma can be used in combination with pembrolizumab or cisplatin. It is not metabolized by much of the liver but excreted via the urine.
References
Pemetrexed Pathway References
Fuld AD, Dragnev KH, Rigas JR: Pemetrexed in advanced non-small-cell lung cancer. Expert Opin Pharmacother. 2010 Jun;11(8):1387-402. doi: 10.1517/14656566.2010.482560.
Pubmed: 20446853
Lansiaux A, Lokiec F: [Pemetrexed: from preclinic to clinic]. Bull Cancer. 2007;94 Spec No Actualites:S134-8.
Pubmed: 17845983
Rollins KD, Lindley C: Pemetrexed: a multitargeted antifolate. Clin Ther. 2005 Sep;27(9):1343-82. doi: 10.1016/j.clinthera.2005.09.010.
Pubmed: 16291410
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings